Fact-checked by Grok 2 weeks ago

Strangles

Strangles is a highly contagious bacterial primarily affecting the upper of horses, donkeys, and other equids, caused by the gram-positive bacterium equi subsp. equi, and is characterized by fever, mucopurulent nasal discharge, and abscessation of the submandibular and . The , also known as equine distemper, has an of 3–14 days and is most severe in young horses aged 1–5 years, with morbidity rates approaching 100% in susceptible populations but a low mortality rate of 1–10% in uncomplicated cases. Transmission occurs through direct contact with infected animals or indirect contact via contaminated equipment, feed, water, or aerosols from nasal discharge, making outbreaks common in densely populated settings like stables or shows; recent trends as of 2025 show increased cases in regions such as the and . Clinical signs typically begin with a sudden fever of 103–106°F (39.4–41.1°C), followed by depression, anorexia, and serous to purulent nasal discharge that may contain pus-filled "strangles" abscesses rupturing externally. Complications, affecting up to 10% of cases, include internal abscessation (bastard strangles) spreading to other organs or immune-mediated purpura hemorrhagica, which can lead to and . Diagnosis is confirmed through bacterial culture or (PCR) testing of nasal swabs, guttural pouch lavages, or aspirates, with PCR offering higher sensitivity for detecting carriers. Treatment focuses on supportive care, including , , and medications, while antibiotics such as penicillin are reserved for severe cases to avoid prolonging the infection and hindering immunity development; surgical drainage of mature may also be necessary. Prevention relies on strict measures, such as quarantining new arrivals for 2–3 weeks with daily monitoring, disinfection of , and with intranasal or intramuscular products, though provide only partial protection and are recommended for high-risk horses; a newer , Strangvac, available in as of 2025, offers additional options for reducing severity. Strangles is a reportable in the United States, emphasizing its global significance in equine health management.

Overview

Definition

Strangles is an acute, highly contagious bacterial disease primarily affecting the upper respiratory tract of equids, characterized by inflammation and abscessation of the lymphoid tissues in the head and neck region. It is caused by the gram-positive bacterium Streptococcus equi subspecies equi (S. equi), a host-adapted pathogen that leads to high morbidity rates, often approaching 100% in susceptible populations. The primary hosts are horses, donkeys, and mules within the Equidae family, with the disease manifesting most severely in young animals aged 1–5 years. Key clinical features include fever, mucopurulent nasal discharge, and swelling of the submandibular and , which often progress to formation and rupture. The typically ranges from 3 to 14 days, after which infected animals shed the via nasal secretions and from ruptured abscesses, facilitating rapid spread within herds. While mortality is generally low (around 2%), complications can arise in severe cases, underscoring the disease's potential for widespread disruption in equine populations. Strangles imposes a substantial economic burden on the equine industry due to the costs of , , , and lost productivity during outbreaks. Individual outbreaks can affect hundreds of and exceed £300,000 in management expenses, including veterinary care and measures, making it a persistent challenge for horse owners and facilities worldwide.

History

Strangles, an infectious disease affecting horses, was first described in 1251 by Jordanus Rufus, an veterinary surgeon serving in the court of Emperor Frederick II, who detailed its characteristic fever and abscessation as a respiratory affliction in equines. This early account marked one of the initial formal recognitions of the condition in veterinary literature, predating modern by centuries and highlighting its longstanding presence in equine populations across . Subsequent medieval and early modern texts, such as those from the , continued to reference similar symptoms, emphasizing the disease's contagious nature and impact on health without identifying a specific cause. The name "strangles" originated from the severe respiratory distress and choking sensation caused by abscesses in the , which could obstruct the airway and lead to suffocation in affected horses; this terminology reflects the dramatic clinical presentation observed by practitioners. A pivotal advancement came in 1888 when German veterinarian Friedrich Schütz isolated the causative bacterium, Streptococcus equi equi, from infected horses, providing the first microbiological confirmation of the and shifting understanding from empirical observations to bacteriological science. This discovery facilitated targeted research, including early attempts in the late 19th and early 20th centuries using live and killed bacterial preparations, though initial efforts yielded inconsistent protection. Throughout the 19th and early 20th centuries, strangles posed significant challenges during military campaigns, particularly in World War I, where dense concentrations of transport and cavalry horses in Allied and Central Powers armies led to widespread outbreaks, exacerbating losses alongside battle injuries and other infections. For instance, British veterinary reports from the era documented strangles as a recurrent issue in remount depots and front-line units, contributing to the deaths of millions of equines and straining logistics. Management practices evolved from rudimentary isolation and lancing of abscesses in the 19th century—based on recognition of contagion through shared stables and equipment—to more systematic quarantine protocols and serological testing by the mid-20th century, informed by bacteriological insights and aimed at curbing transmission in large-scale equine operations. These developments underscored strangles' enduring role in shaping veterinary strategies for equine infectious diseases. Despite over a century of research and control efforts, strangles persists globally, with a significant rise in UK cases reported in 2025 (over 70 more than in 2024 as of October) and recent genomic studies revealing key transmission drivers to inform better prevention.

Etiology and Transmission

Causative Agent

Strangles is caused by Streptococcus equi subsp. equi (S. equi), a Gram-positive, beta-hemolytic coccus classified within Lancefield group C. This bacterium is highly host-adapted, acting as an obligate pathogen exclusive to equids such as horses, donkeys, and mules, with no known natural reservoirs in other species. The genome of S. equi is a circular chromosome approximately 2.3 Mb in size, encoding around 2,100 protein-coding genes. It exhibits about 80% sequence identity with the human pathogen Streptococcus pyogenes, reflecting their shared ancestry within the pyogenic group of streptococci, though S. equi has undergone specialization with gene loss and acquisition that restrict it to equine hosts. A key genomic feature is the sem gene, which encodes the SeM protein, an M-like surface protein that contributes to immune evasion by binding equine fibrinogen and inhibiting phagocytosis. Virulence in S. equi is driven by several factors that enable , , and formation. The capsule, which is non-antigenic and mimics host , shields the bacterium from opsonization and , facilitating intracellular survival and persistent infection. Streptolysin S, a membrane-damaging , promotes to host cells, while activates plasminogen to , aiding in and bacterial dissemination through tissues, which contributes to the characteristic abscesses. The protein further supports to host epithelial cells and evasion of killing, enhancing the bacterium's ability to colonize and form suppurative lesions. S. equi is differentiated from its close relative Streptococcus equi subsp. zooepidemicus (S. zooepidemicus), which shares over 95% genomic similarity but functions primarily as an opportunistic commensal in the upper of equids and other animals, occasionally causing under stress conditions. Unlike S. equi, S. zooepidemicus retains broader host range capabilities and can ferment , whereas S. equi has evolved through reductive , losing metabolic genes and gaining equine-specific virulence elements that make it incapable of asymptomatic carriage or zoonotic transmission.

Transmission Mechanisms

Strangles, caused by Streptococcus equi subsp. equi, spreads primarily through direct contact between horses, particularly nose-to-nose interactions involving nasal secretions or purulent material from ruptured abscesses. Indirect transmission occurs via contaminated fomites such as shared equipment, feed, water troughs, and handler clothing, which can transfer the bacteria to susceptible animals. The bacterium demonstrates notable environmental persistence on surfaces, facilitating fomite-mediated spread; S. equi can survive for up to 63 days on wood at 2°C or 48 days on glass and wood at 20°C in controlled conditions, with viability extending beyond 30 days in cool, moist indoor environments but declining rapidly under desiccation, heat, or sunlight exposure. Asymptomatic carriers play a critical role in prolonged transmission, as up to 40% of infected horses develop persistent infections in the guttural pouches, where bacteria form chondroids and shed intermittently into nasal secretions for weeks to years, potentially up to 18 months or longer in rare cases. Transmission risk escalates in settings with high-density stabling, of naive and previously exposed horses, and international transport, compounded by an of 3–14 days that allows silent spread within populations.

Infection Process

Streptococcus equi, the causative agent of strangles, primarily enters the equine host through the or oral cavity following or of contaminated material. Upon entry, the bacteria adhere to cells in the crypts of the lingual and palatine tonsils, as well as the follicle-associated epithelium of the pharyngeal and tonsils, using surface ligands such as SzPSe, Se73.9, and Se51.9 to facilitate . This initial attachment allows penetration into deeper tonsillar tissues within hours of exposure. From the tonsillar sites, S. equi rapidly translocates via lymphatic drainage to regional lymph nodes, including the submandibular, retropharyngeal, and mandibular nodes, often within 3 hours post-infection. In these lymphoid tissues, the bacteria proliferate extracellularly, evading early clearance through virulence factors like the capsule and protein, which inhibit by neutrophils attracted via complement-derived chemotactic signals. This leads to suppurative lymphadenitis, characterized by the formation of neutrophilic abscesses that mature over 3-5 days, encapsulated by a fibrinous wall to contain the infection. The infection progresses through distinct stages. The lasts 3-14 days, during which bacterial replication in the triggers fever onset via pyrogenic exotoxins such as SePE-H and SePE-I. The acute phase involves abscess maturation in the affected lymph nodes over 7-14 days, with bacterial chains expanding within the purulent core. Resolution occurs as rupture 1-4 weeks post-infection, releasing laden with viable bacteria into surrounding airways or externally, facilitated by enzymes like streptolysin S and that promote tissue breakdown. S. equi exhibits a strong for mucosal surfaces of the upper and associated lymphoid tissues, particularly the pharyngeal region and draining lymph nodes of the head and neck. In rare cases, approximately 28% in some outbreaks, metastatic dissemination via hematogenous or further lymphatic spread can occur, leading to "bastard strangles" with abscesses in distant sites such as the , , or .

Immune Response

The innate immune response to equi infection in horses is characterized by rapid recruitment to the tonsils and regional nodes, such as the mandibular and retropharyngeal nodes, leading to heavy infiltration and the formation of purulent abscesses. This influx, triggered shortly after bacterial colonization, contributes to the characteristic swelling and suppuration observed in strangles. Concurrently, pro-inflammatory release, including elevated levels of IL-6, TNF-α, IL-1, and IL-8, drives systemic fever, inflammation, and the acute phase response, exacerbating tissue damage and clinical signs like pyrexia and nasal discharge. The adaptive involves both humoral and cellular components, with a robust antibody-mediated targeting key bacterial antigens. Horses develop systemic IgG and mucosal IgA antibodies primarily against the M-like surface protein , which opsonizes bacteria for and neutralizes activity, aiding in bacterial clearance from the nasopharynx. T-cell responses, including non-specific activation by S. equi , contribute to and swelling, while specific T-helper cells support B-cell and formation. These responses typically peak 2-3 weeks post-infection, coinciding with resolution of mucosal shedding and maturation. In most cases, recovery from strangles confers protective immunity lasting at least five years in 70-75% of , mediated by persistent anti-SeM antibodies and memory T-cells that prevent clinical disease upon re-exposure. However, this immunity is often incomplete against carriage, allowing persistent nasopharyngeal or pouch colonization in a subset of recovered . Pathological aspects of the immune response can lead to complications, including reactions upon reinfection or repeated exposure, such as purpura hemorrhagica, an immune-mediated causing and hemorrhage. In severe cases, overwhelming infection or dysregulated superantigen-induced T-cell activation may result in , facilitating metastatic abscessation (bastard strangles) in distant lymph nodes or organs.

Clinical Features

Signs and Symptoms

Strangles typically manifests after an of 3 to 14 days following exposure to Streptococcus equi subsp. equi. The earliest clinical signs include a sudden onset of high fever, often reaching 103° to 106°F (39.4° to 41.1°C), accompanied by , anorexia, and a serous nasal discharge that appears within 1 to 3 days of the fever spike. These initial symptoms reflect the acute inflammatory response in the upper and may precede more overt signs by 24 to 48 hours. As the disease progresses, the hallmark features emerge, characterized by bilateral enlargement of the , which become firm, painful, and abscessed. Retropharyngeal swelling often develops concurrently, leading to , respiratory , and the characteristic "strangling" appearance due to external in the throatlatch region. The nasal discharge evolves from serous to purulent, typically white or yellow in color, and the submandibular abscesses may rupture externally or drain into the guttural pouches, releasing thick pus and facilitating bacterial shedding. In uncomplicated cases, spontaneous resolution occurs within 2 to 3 weeks as the abscesses drain and the horse's clears the infection, though clinical recovery may extend to 3 to 6 weeks in some instances. Clinical presentations can vary based on the horse's age and prior immunity. In previously exposed or immune , the disease may be mild or subclinical, manifesting only as transient mucoid nasal discharge, mild fever, and minimal involvement without abscessation. Conversely, foals and young often experience more severe forms, including generalized with widespread abscessation beyond the head and neck. While most cases resolve without long-term effects, there is a potential for immune-mediated complications such as hemorrhagica in susceptible individuals.

Complications

Complications of strangles in , while uncommon, can significantly worsen outcomes and require intensive veterinary . These secondary conditions arise from metastatic of or aberrant immune responses, affecting approximately 20% of cases. Overall mortality from strangles remains low at less than 10%, but rates can approach 8% in complicated cases, with fatalities often linked to airway obstruction, internal abscessation, or immune-mediated sequelae. Bastard strangles, also known as metastatic strangles, involves the dissemination of Streptococcus equi to distant lymph nodes or organs, leading to internal formation in sites such as the lungs, (e.g., , liver, , ), , or rarely the . This condition manifests as , , or neurological signs like , occurring in about 2% of infected horses in documented outbreaks. Diagnosis typically requires imaging or exploratory procedures, and severe cases may necessitate due to organ compromise. Purpura hemorrhagica is an immune-mediated that develops 2-4 weeks after initial , triggered by high titers against S. equi surface proteins. It presents with subcutaneous in the limbs, head, and trunk; petechial hemorrhages; and potential or , affecting roughly 6.5% of cases and correlating with in affected horses. Skin sloughing may occur in severe instances, and the condition responds to immunosuppressive alongside supportive . Guttural pouch empyema results from the rupture of retropharyngeal abscesses into the guttural pouch, causing chronic accumulation of and potential chondroid (mineralized concretions) formation. This is observed in some post-infection, with studies reporting it in up to 64% of cases examined endoscopically; overall carrier rates are estimated at 10-40%. It can lead to , respiratory , or secondary mycosis if untreated. Endoscopic evaluation and lavage are essential for detection and management to prevent carrier status. Less common complications include immune-mediated , which may cause cardiac arrhythmias, and septicemia in neonates, leading to rapid . These, along with , contribute to higher mortality in vulnerable populations, though overall fatalities from strangles are rare outside of severe metastatic or immune events.

Diagnosis

Clinical Assessment

Clinical assessment of strangles begins with a thorough taking to identify potential risk factors and the timeline of onset. Veterinarians inquire about recent to infected or premises, including with animals of unknown health status or attendance at events with high density, as well as travel that may have facilitated contact with carriers. The incubation period is typically 3 to 14 days post-exposure, with fever often appearing 24 to 48 hours before other signs, helping to correlate symptoms with recent events. During the , rectal temperature is measured at least twice daily, as pyrexia exceeding 38.5°C is a hallmark early indicator prompting immediate suspicion of strangles. of the submandibular and is essential to detect enlargement, heat, pain, or fluctuance indicative of abscessation, with careful attention to avoid rupture that could spread . Nasal may be performed to visualize the source of any , assessing the and guttural pouches for or while minimizing of bacteria. Clinical severity is often evaluated using scoring indices to guide management decisions, such as duration. One such system assigns points for fever (rectal >38.2°C: 1 point), ( count ≥14.0 × 10³/μL: 1 point), nasal discharge severity (0–5 points based on volume and character), lymph node swelling (0–3 points graded by size and firmness), and abscessation or rupture (4 points); a total score of ≥4 classifies the case as clinical strangles and supports prolonged isolation. These indices help prioritize horses for closer monitoring and inform measures without relying on laboratory confirmation. Isolation protocols are initiated immediately upon suspicion to curb , separating potentially affected horses into designated groups: "red" for those showing clinical signs, "amber" for exposed but individuals, and "green" for unaffected horses. Suspect animals are moved to a dedicated area with dedicated equipment, and personnel use while handling cases last in the daily routine; typically lasts at least three weeks beyond resolution of signs in the last case.

Laboratory Confirmation

Laboratory confirmation of strangles involves microbiological and molecular tests to detect Streptococcus equi subsp. equi (S. equi) in clinical samples, providing definitive evidence beyond clinical suspicion. These methods are essential for identifying active infections, carriers, and distinguishing S. equi from related streptococci like S. zooepidemicus. Bacterial remains a standard technique for isolating S. equi, using swabs from the nasopharynx, nasal washes, or from abscessed lymph nodes. Samples are inoculated onto selective such as Columbia colistin-nalidixic acid with 5% sheep blood, where S. equi forms small (1 mm), translucent colonies exhibiting clear beta-hemolysis after 24-48 hours of at 37°C. sensitivity testing is performed on isolates to guide , though sensitivity can be as low as 40% in early or chronic stages due to fastidious growth requirements or low bacterial loads. yields the highest recovery rates, with results available in 1-2 days. Polymerase chain reaction (PCR) assays offer rapid, highly sensitive detection of S. equi DNA, particularly useful for early diagnosis and carrier screening, with sensitivities exceeding 95% compared to culture. PCR targets specific genes such as eqbE (encoding a putative secreted protein), seeI (), or SEQ2190, often in multiplex formats including internal controls for validation. Suitable samples include nasopharyngeal swabs or washes collected 2-3 days post-fever onset, as well as guttural pouch lavages; results are typically available within 24-48 hours and detect both viable and non-viable , making PCR 3 times more sensitive than culture overall. Serological testing via enzyme-linked immunosorbent assay () detects antibodies against S. equi antigens, aiding in confirming recent exposure or persistent in carriers. The SeM ELISA measures IgG to the M-like protein SeM, with titers rising 2-3 weeks post-, peaking at 5 weeks, and persisting for 6 months or longer; paired serum samples showing fourfold increases indicate active disease. Combined ELISAs incorporating SeM and Antigen A (SEQ_2190) enhance specificity by reducing with S. zooepidemicus. These tests are particularly valuable for subclinical cases but do not distinguish from natural . Endoscopic examination of the guttural pouches, combined with lavage, is crucial for detecting carriers with or chondroids, where up to 10% of recovered harbor persistent . A flexible visualizes inflammation, pus, or abscesses, followed by saline lavage through the biopsy channel for subsequent culture or analysis, yielding high detection rates in this reservoir. In cases of suspected chondroid formation or persistent suppuration, biopsy samples may reveal consistent with suppurative inflammation, including neutrophilic infiltrates and bacterial colonies. This approach is recommended for with negative nasal but ongoing concerns.

Treatment

Supportive Care

Supportive care forms the cornerstone of managing strangles in horses, focusing on alleviating discomfort, supporting natural immune processes, and preventing secondary issues without relying on antimicrobials as the primary . This approach is suitable for most uncomplicated cases, where the disease typically resolves within 2-3 weeks following formation and drainage, allowing the horse's to develop protective responses. Strict isolation and measures are essential to contain and protect mates. Affected horses must be d immediately upon detection of fever or clinical signs, with separation into distinct groups for clean, exposed, and sick animals; should continue until clinical signs have resolved and bacterial clearance is confirmed by negative bacteriologic cultures or testing from nasopharyngeal washes or guttural pouch lavages, typically taking 4-6 weeks but potentially longer to account for prolonged bacterial shedding. Stalls and equipment require daily disinfection using (1:32 dilution of ) or equivalent quaternary ammonium compounds after removing organic debris, with facilities rested for at least 2 weeks in dry conditions to ensure bacterial inactivation. , including gloves and dedicated clothing, must be worn when handling infected horses, with handlers progressing from clean to sick animals to avoid cross-contamination. Symptom relief emphasizes environmental and topical support to reduce and promote recovery. Horses should be housed in a warm, dry, dust-free stall to minimize respiratory irritation and stress. Non-steroidal anti-inflammatory drugs, such as flunixin meglumine (1.1 mg/kg IV or orally once daily) or (2-4 mg/kg orally once daily), are administered judiciously to control fever, inflammation, and associated discomfort, improving appetite without suppressing development. Hot compresses or poultices applied to submandibular or for 15-20 minutes several times daily encourage maturation and spontaneous drainage of abscesses. In severe cases with respiratory distress from , temporary tracheostomy may be necessary to maintain airway patency. Nutritional support addresses common challenges like and reduced intake due to pharyngeal swelling. Soft, moist, highly palatable feeds—such as soaked hay pellets or mashes—should be offered at ground level to facilitate eating, while ensuring constant access to fresh water. In cases of severe or prolonged anorexia, for fluid and nutrient delivery may be required, with intravenous fluids considered if develops. Regular of status, including skin tenting tests and assessment, is critical to detect and address early, as affected are prone to fluid losses from fever and poor intake. Wound management targets post-rupture care to promote healing and prevent contamination. Once abscesses drain, the sites should be gently flushed daily with a 3-5% solution or dilute until purulent discharge resolves, typically over 3-5 days, to reduce bacterial load and encourage . Bandaging the affected areas, particularly on the head or neck, helps shield open wounds from fly strikes and environmental contaminants, using absorbent materials changed frequently to maintain cleanliness. Topical ichthammol ointments may be applied prior to bandaging to soften and draw out residual if needed.

Antimicrobial Therapy

Antimicrobial therapy for strangles, caused by Streptococcus equi subsp. equi, is reserved for specific clinical scenarios to target the while minimizing risks to immunity development. Indications include early infection within 24-48 hours of fever onset to halt bacterial dissemination and shedding, severe cases with high fever (>103°F or 39.4°C), profound , respiratory distress from , or complications such as metastatic abscessation and guttural pouch . Routine use is not recommended for uncomplicated cases once abscesses form, as it can prolong the disease course by delaying maturation and drainage, thereby impairing the development of protective immunity. The preferred antimicrobial is penicillin G, administered at 22,000 IU/kg intramuscularly every 12 hours for 7-10 days, due to its against S. equi and the bacterium's consistent susceptibility to beta-lactams. Alternatives include (2.2 mg/kg IV or IM every 12 hours, or extended-release formulations at 6.6 mg/kg IM every 96 hours) for horses intolerant to frequent injections, and trimethoprim-sulfadiazine (30 mg/kg orally every 12 hours) when penicillin is contraindicated, though can vary. Resistance to these agents remains rare, but culture and sensitivity testing should guide selection in suspected refractory cases. Challenges in therapy arise from S. equi's ability to persist intracellularly within macrophages and form biofilms in guttural pouches, potentially evading antibiotics and leading to carrier states that require prolonged treatment (up to 3-4 weeks) or adjunctive procedures like lavage. Early or inappropriate antibiotic initiation can heighten the risk of purpura hemorrhagica, an immune-mediated vasculitis, particularly in horses with high serum antibody titers (≥1:3,200), by altering antigen exposure and promoting aberrant immune responses. Monitoring involves serial clinical assessments, including fever resolution and status, alongside bacteriologic cultures or from nasopharyngeal washes or guttural pouch lavages to confirm bacterial clearance. Therapy should cease once abscesses begin draining to facilitate immunity, with retesting for carriers recommended 3 weeks post-treatment; supportive measures, such as hot packing, may complement therapy during this period.

Prevention

Vaccination Strategies

Vaccination remains a key strategy for mitigating strangles in horses, though available vaccines provide only partial protection against equi subsp. equi. In the United States, two primary types are licensed by the USDA: intramuscular (IM) killed vaccines, such as Strepvax II, which use inactivated bacterial extracts including M-protein to stimulate systemic immunity; and intranasal (IN) modified-live vaccines, such as Pinnacle I.N., which employ avirulent strains to induce mucosal immunity at the site of natural infection. Standard protocols for IM vaccines like Strepvax II involve a primary series of three 1 mL doses administered three weeks apart, followed by annual boosters to maintain immunity. For IN vaccines like Pinnacle I.N., the regimen consists of two doses given two to three weeks apart in healthy horses aged nine months or older, with annual revaccination recommended for at-risk animals. is risk-based, prioritized for horses in endemic areas or with high exposure potential, and should be avoided during active outbreaks to minimize adverse reactions and complications. Efficacy varies by vaccine type, with IM killed vaccines reducing clinical disease incidence by approximately 50% after boosting, while IN modified-live vaccines demonstrate higher protection rates against experimental challenges, often exceeding 70% reduction in clinical signs. Overall, vaccines achieve 50-80% reduction in severity but offer poor prevention of the state, where up to 10% of recovered horses harbor persistent S. equi infections. Common side effects include local reactions such as injection-site soreness or abscesses for IM vaccines, and transient nasal discharge, mild fever, or submandibular lasting 1-7 days for IN vaccines; severe is rare but requires epinephrine treatment. In , Strangvac, a recombinant administered intramuscularly, has been available since 2022 and targets proteins to reduce both clinical disease and carrier states. It involves two doses given one month apart for horses at medium to high risk, showing safety and efficacy in reducing strangles signs in field studies as of 2025. Ongoing research continues to address gaps in current products, particularly for US-licensed vaccines, with efforts focusing on further improvements in novel subunit formulations to enhance cross-protection, duration of immunity, and elimination of persistent infections.

Biosecurity Measures

Biosecurity measures for strangles focus on preventing the introduction and limiting the spread of Streptococcus equi within populations through structured protocols that emphasize , , and . protocols are essential for new arrivals, requiring a minimum period of 3 weeks in a designated area separate from the resident to allow for of clinical signs such as fever or nasal . During this time, daily checks are conducted, and diagnostic testing includes on nasal swabs or nasopharyngeal washes to detect active shedding, alongside to assess prior exposure and immune status. This approach ensures that potentially infected horses are identified before integration, reducing the risk of herd-wide outbreaks. Facility design plays a critical role in minimizing indirect transmission via fomites and environmental . Stables should feature separate systems to avoid aerosolized between groups, with wards located at least 10-25 meters from main housing to prevent nose-to-nose contact. Footbaths containing disinfectants like 1:10 diluted or peroxygen compounds should be placed at all entrances and exits, particularly during high-risk periods, to decontaminate and reduce mechanical transfer by personnel. Dedicated equipment, such as buckets, grooming tools, and hoses, must be assigned to specific groups and disinfected regularly with agents like or to eliminate bacterial persistence on surfaces. Visitor restrictions are strictly enforced during outbreaks, limiting access to essential personnel who must change clothing, use protective gear, and follow unidirectional handling to avoid cross-contamination between clean and affected areas. These measures target the primary routes of direct contact and contaminated fomites. Screening protocols enhance by identifying carriers, who can harbor S. equi in the pouches for months. Pre-purchase evaluations routinely include pouch to visualize or chondroids, combined with lavage for testing, which offers high sensitivity for detecting low-level shedding. For high-risk populations like show horses, which frequently travel and commingle, routine screening on nasopharyngeal samples or pouch lavages is recommended every 3-6 months or post-event to monitor for subclinical infections. Three consecutive negative tests, spaced 7 days apart, are required to confirm clearance in suspected carriers. Outbreak control relies on rapid implementation of containment strategies to trace and isolate exposed horses. Movement records, including transport logs and event attendance, are reviewed to identify contacts, enabling targeted of at-risk individuals for up to 6 weeks post-exposure if shedding persists. Affected premises are placed under full , with twice-daily monitoring and using separate caretakers for sick, exposed, and clean groups. While of persistent carriers has been employed in severe outbreaks leading to significant morbidity, standard protocols prioritize isolation and repeated testing over depopulation unless economically or logistically unfeasible. Pastures used by infected horses should rest for 2-6 weeks, depending on environmental conditions, before reuse to allow bacterial die-off.

Prognosis and Epidemiology

Outcomes and Recovery

In uncomplicated cases of strangles, horses typically recover within 3 to 6 weeks, with clinical signs such as fever and abscessation resolving as the clears the equi infection. During this period, bacterial shedding from nasal passages or abscesses usually persists for 2 to 3 weeks after the fever subsides, though supportive care can shorten the acute phase. Approximately 70% to 75% of surviving horses that are not treated with develop protective immunity lasting at least 5 years, reducing the risk of reinfection, while use may interfere with this immune development. Prognosis is generally favorable for most cases, with overall mortality rates below 10%, though this rises to 40% or higher when complications such as bastard strangles or purpura hemorrhagica occur in about 10% of infections. Key factors influencing outcomes include the horse's age, with foals and aged 1 to 5 years experiencing more severe due to or waning immunity, respectively; early supportive , which improves rates by preventing abscess rupture and secondary infections; and the absence of complications, which otherwise prolong . Recurrence is uncommon in non-carrier horses but can occur in up to 25% of cases if prior suppresses full immunity development. Post-recovery, 10% to 40% of infected become carriers, harboring S. equi in the pouches for months to years and intermittently shedding the , which can perpetuate outbreaks. Long-term effects primarily involve chronic pouch or chondroid formation in carriers, leading to persistent respiratory obstruction, , or recurrent infections that may diminish athletic performance in sport by reducing stamina and increasing susceptibility to . Morbidity remains high during outbreaks, affecting nearly 100% of susceptible in a herd, but full return to pre-infection health is expected in uncomplicated survivors without carrier status.

Global Distribution

Strangles, caused by Streptococcus equi subspecies equi, is endemic in horse populations worldwide, with the exception of , where strict import bans have maintained disease-free status. Outbreaks are frequently reported in , , and , where the disease remains one of the most common infectious conditions in equines. In , strangles is emerging as a concern, with genetic analyses identifying multiple strains in countries such as , , and the . Key risk factors for strangles outbreaks include intensive equine industries, such as and showing events, which facilitate and close contact among large populations. International horse trade and movement without adequate screening exacerbate spread, as carriers can transport the bacterium across borders. The disease exhibits seasonal peaks in spring months, particularly May in , though risk increases during periods of close confinement such as winter stabling; outbreaks increase with rising temperatures from winter to spring. Surveillance efforts vary by region but emphasize early detection to curb outbreaks. In the European Union and United Kingdom, voluntary reporting through networks like the Surveillance of Equine Strangles (SES) provides real-time laboratory data, while the United States Department of Agriculture (USDA) monitors strangles as a nationally reportable disease under its Animal and Plant Health Inspection Service (APHIS) guidelines. Molecular techniques, including core-genome multilocus sequence typing (cgMLST), have revealed distinct regional strains, such as Bayesian population structure (BAPS) cluster 2 dominating in Europe and BAPS-1 prevalent in North America, aiding in tracing transmission pathways. As of 2025, strangles outbreaks continue globally, with over 370 laboratory-confirmed cases reported in the UK by October, incidents in the US (e.g., Maryland in August affecting 17 horses), and nine outbreaks in Canada during the first quarter; a July 2025 genomic study by the Royal Veterinary College identified key transmission drivers in UK horses using whole-genome sequencing. Control trends show declining incidence in regions with robust vaccination and biosecurity programs; for instance, intranasal vaccines like Pinnacle IN have contributed to reduced outbreak frequency in vaccinated U.S. stables, where annual infection rates can fall below 1% in managed facilities. Pre-import screening protocols, such as dual-antigen ELISA tests, have similarly lowered risks in high-movement areas like the Middle East. However, strangles persists at higher levels in developing regions, including parts of Asia and Africa, where limited access to vaccines and biosecurity measures sustains endemic transmission, as evidenced by prevalence rates exceeding 19% in some Egyptian horse populations.

References

  1. [1]
    Strangles in Horses - Respiratory System - Merck Veterinary Manual
    Treatment of uncomplicated cases primarily relies on supportive care, with administration of antimicrobials recommended for complicated cases. Prevention and ...
  2. [2]
    Strangles | School of Veterinary Medicine
    Aug 10, 2020 · Strangles is a highly contagious disease of the equine upper respiratory tract caused by the bacterium Streptococcus equi subspecies equi (S. equi).
  3. [3]
    Strangles | Equine Disease Communication Center
    Treatment: Supportive care is the primary treatment. Use of antibiotics in infected horses is restricted to those with severe clinical signs such as respiratory ...
  4. [4]
    [PDF] AAEP Infectious Disease Guidelines: Strangles
    Receiving Animals. Zoonotic Potential. Definition The upper respiratory disease commonly referred to as strangles is caused by Streptococcus equi subsp equi. ...
  5. [5]
    Globetrotting strangles: the unbridled national and international ...
    The equine disease strangles, which is characterized by the formation of abscesses in the lymph nodes of the head and neck, is one of the most frequently ...
  6. [6]
    Strangles: a pathogenic legacy of the war horse - PubMed
    Strangles, characterised by pyrexia followed by abscessation of the lymph nodes of the head and neck, was first described in 1251 (Rufus 1251) and the ...
  7. [7]
    The persistence of equine strangles
    Dec 8, 2022 · ... Streptococcus equi subspecies equi (S. equi ), first identified by Schütz (1888), have likely been around for much longer. In the 17th ...
  8. [8]
    [PDF] Understanding Equine Strangles: Signs of Disease, Management ...
    The disease has been in the equine population for centuries, and was first reported in 1251. The infection is highly contagious in horse populations and can ...Missing: descriptions ancient
  9. [9]
    Genome specialization and decay of the strangles pathogen ... - NIH
    Strangles is one of the oldest recognized infectious diseases of horses and continues to cause significant welfare and economic costs throughout the world. The ...Missing: ancient | Show results with:ancient
  10. [10]
    Strangles Vaccines and Immunity to Streptococcus equi - The Horse
    Jul 14, 2006 · Vaccination was first attempted over 100 years ago with a variety of live and killed preparations of S. equi. Studies in Australia in the early ...
  11. [11]
    Veterinary Corps - World War I Centennial site
    Among these unfortunate horses there was strangles in all its colorful variations; pneumonia and serofibrinous pleurisy; purpura hemorrhagica and pink eye; ...
  12. [12]
    Advances in the understanding, detection and management of ...
    Jun 28, 2023 · equi), first identified by Schütz (1888) ... (2000) Streptococcus equi with truncated M-proteins isolated from outwardly healthy horses.Streptococcus Equi · Clinical Management · Serological Testing<|separator|>
  13. [13]
    Streptococcus equi - an overview | ScienceDirect Topics
    equi infection in horses, commonly referred to as “strangles,” was described in early veterinary science literature and first reported by Jordanus Ruffus in ...Missing: ancient | Show results with:ancient
  14. [14]
    Streptococcus equi: a pathogen restricted to one host - PubMed
    Strangles caused by the host adapted Lancefield group C Streptococcus equi subspecies equi (S. equi) is a frequently diagnosed infectious disease of horses ...Missing: Gram- positive beta- hemolytic coccus
  15. [15]
    Genomic Evidence for the Evolution of Streptococcus equi
    Mar 27, 2009 · These pathogens share approximately 80% genome sequence identity with the important human pathogen Streptococcus pyogenes. We sequenced and ...
  16. [16]
    Streptococcus equi Infections in Horses: Guidelines for Treatment ...
    5 Failure of neutrophils to phagocytose and kill the streptococci appears to be due to a combination of the hyaluronic acid capsule, antiphagocytic SeM protein, ...Missing: streptokinase adhesion
  17. [17]
    Streptococcus equi - an overview | ScienceDirect Topics
    Virulence factors for S. equi include a nonantigenic hyaluronic acid capsule, hyaluronidase, streptolysin S, streptokinase, immunoglobulin G (IgG) Fc-receptor ...
  18. [18]
  19. [19]
    Streptococcus equi - an overview | ScienceDirect Topics
    S. equi virulence factors that may account for muscle necrosis include an unidentified cytotoxic protein, several proteases, streptokinase, and streptolysin S.Missing: adhesion | Show results with:adhesion
  20. [20]
    Transmission of Streptococcus equi Subspecies zooepidemicus ...
    Streptococcus equi subspecies zooepidemicus (S. zooepidemicus) is a β-hemolytic, Lancefield group C streptococcal bacterium. S. zooepidemicus is considered an ...<|separator|>
  21. [21]
    Identification of the Novel Streptococcus equi subsp. zooepidemicus ...
    May 23, 2023 · Streptococcus equi sub. zooepidemicus (SEZ) is described as a commensal bacterium of several animal species, including humans.
  22. [22]
    Streptococcus equi subsp. zooepidemicus - VetBact
    Mar 8, 2023 · Purple agar with lactose can be used to differentiate S. equi subsp. zooepidemicus, which is a lactose fermenter, from S. equi subsp. equi, ...
  23. [23]
    Strangles in Horses - Respiratory System - MSD Veterinary Manual
    Transmission is via direct contact with infected horses or with any ... Streptococcus equi infections in horses: guidelines for treatment, control ...
  24. [24]
    Survival of Streptococcus equi on surfaces in an outdoor environment
    The first study reported survival of S. equi for 63 d on wood at 2°C and 48 d on glass or wood at 20°C (3). The other study reported survival ...Missing: fomites | Show results with:fomites
  25. [25]
    [PDF] ACVIM Consensus Statement Streptococcus equi Infections in Horses
    The following consensus statement reflects our current knowledge and opinion about clinical signs, pathogenesis, epidemiology, treatment, complications, and.
  26. [26]
    [PDF] Equine strangles: An update on disease control and prevention
    This review describes general aspects of the disease caused by SEE in horses (clinical signs, pathogenesis, epidemiology, treatment, complications) and then ...
  27. [27]
    None
    ### Summary of Strangles Infection Process (Streptococcus equi in Horses)
  28. [28]
    Early pathogenesis of equine Streptococcus equi infection (strangles)
    At onset of fever, tonsillar tissues and one or more mandibular and retropharyngeal lymph nodes were heavily infiltrated by neutrophils and long chains of ...
  29. [29]
    Strangles
    The organism slowly multiplies in the lymph node. Subsequent migration of neutrophils into the lymph nodes causes swelling and abscessation. Nasal shedding ...
  30. [30]
    Cardiac Troponin I and Immune-Inflammatory Response in Horses ...
    The levels of cTnI, Hp, SAA, TNF-α, and IL-6 were significantly (P < .05) higher in cases compared to control horses. Successfully treated cases had ...
  31. [31]
    Equine Cytokines: Immune Response, Inflammation, and Disease
    Strangles (Streptococcus equi infection): Characterized by an overproduction of pro-inflammatory cytokines such as IL-1 and TNF-α, which contribute to severe ...
  32. [32]
    the most prevalent infectious respiratory disease in horses worldwide
    Streptococcus equi subsp. equi is the causative agent of Strangles in horses, the most common respiratory infectious disease worldwide.
  33. [33]
    Serum and mucosal antibody isotype responses to M-like protein ...
    Equine strangles, caused by the clonal pathogen Streptococcus equi, is a source of serious economic loss despite the widespread use of commercial vaccines.Missing: adaptive | Show results with:adaptive
  34. [34]
    Localised mitogenic activity in horses following infection ... - PubMed
    Streptococcus equi produces superantigens (sAgs), which are thought to contribute to strangles pathogenicity through non-specific T-cell activation and pro- ...
  35. [35]
    The hygienic aspects in the management of strangles - Fridberg - 2023
    Apr 5, 2023 · Two to 3 weeks after infection, mucosal and systemic immune responses are stimulated, coinciding with mucosal clearance of S. equi (Boyle et al.
  36. [36]
  37. [37]
    Understanding Strangles in Horses: Symptoms, Treatment, and ...
    Feb 12, 2025 · Strangles is a highly contagious equine disease that affects the upper respiratory system. Streptococcus equi invades the lymph nodes around the throat and jaw.
  38. [38]
    Strangles in horses | UMN Extension
    Quick facts. Strangles is a highly contagious infection that causes fever, nasal discharge and abscesses near swollen lymph nodes.
  39. [39]
    Strangles - Horse - B&W Equine Vets
    Once infection develops most horses will be unwell for 1-3 weeks. After this time, the vast majority will make a full recovery, though around 10% of cases may ...Missing: uncomplicated | Show results with:uncomplicated
  40. [40]
    What is strangles? | Redwings Horse Sanctuary
    Strangles is an extremely contagious illness that affects the horse's upper respiratory tract. It is the most common infectious disease in the UK and worldwide.
  41. [41]
    [PDF] Strangles - American Association of Equine Practitioners
    Strangles commonly affects young horses (weanlings and yearlings), but horses of any age can be infected. Vaccination against S. equi is recommended on premises ...
  42. [42]
    Strangles: Serious, But Not Often Fatal - The Horse
    Jan 30, 2009 · “Another complication is called purpura haemorrhagica, in which horses develop fluid swelling or edema in their lower limbs from acute ...Missing: hemorrhagica | Show results with:hemorrhagica
  43. [43]
    [PDF] Equine Strangles Fact Sheet - Georgia Department of Agriculture
    May 19, 2008 · “Bastard Strangles” occurs due to immune system failure or overwhelming and rapid spread of the bacteria throughout the body. According to the ...<|control11|><|separator|>
  44. [44]
    Could we eradicate strangles in equids? in - AVMA Journals
    Aug 1, 2007 · Strangles need not be an inevitable fate for most horses and should be consigned to the archaeologic trash can where it belongs. General ...<|control11|><|separator|>
  45. [45]
    Strangles in Horses: Predicting Disease and Complications
    Jun 27, 2016 · A high percentage of horses will develop empyema, so guttural pouch endoscopy is recommended at the end of the course of disease to make sure ...
  46. [46]
    Decreased Clinical Severity of Strangles in Weanlings Associated ...
    28 ene 2018 · Based on clinical scoring at the time of nasal sampling, 34 of 112 horses had clinical scores of ≥4 and thereby were classified as having ...
  47. [47]
  48. [48]
    Streptococcus equi subsp. equi - VetBact
    Mar 8, 2023 · Small (about 1 mm in diameter) transluscent colonies after incubation for 24 h at 37°C on blood agar. Give (clear) beta-hemolysis on blood agar.
  49. [49]
    Rapid diagnosis of strangles (Streptococcus equi subspecies equi ...
    Strangles is one of the most common equine infectious diseases with serious health, welfare and socio-economic impact. However, the detection of ...Missing: tgase | Show results with:tgase
  50. [50]
    Laboratory Diagnosis of Strangles - The Horse
    Jul 10, 2017 · Bacteriologic Culture. Nasal swabs and nasopharyngeal washes collected two to three days after fever onset in the acute phase of strangles and ...
  51. [51]
    Strepvax II - Equine Strangles Vaccine
    Strepvax II has been shown to be effective for the vaccination of healthy horses against Streptococcus equi, the cause of strangles in horses. Learn more.
  52. [52]
    Pinnacle® I.N. | For Animal Healthcare Professionals - Zoetis
    Pinnacle® I.N. is the only two-dose modified-live vaccine developed to help prevent strangles caused by S. equi. Pinnacle® I.N. utilizes a specially designed ...
  53. [53]
    Development of novel Streptococcus equi vaccines with an ... - NIH
    May 3, 2024 · To stimulate a systemic immune response, most immunization regimens against strangles have relied on intramuscular injections of vaccines.
  54. [54]
    [PDF] Biosecurity Tips for Horse Owners - usda aphis
    Also, put a footbath at the entrance and exit to the isolation area, and keep coveralls and boots or plastic foot covers near the sick horse isolation area.
  55. [55]
    A herd outbreak of equine strangles
    A severe strangles outbreak occurred in 2017 in Kansas, which resulted in many horses being ill, several horses having to be euthanized due to significant ...
  56. [56]
  57. [57]
    Strangles: Understanding Equine Distemper and Purpura ...
    Nov 29, 2012 · The classic symptom of the infection is swollen lymph nodes beneath the jaw or throat areas or in other external and/or internal body locations.<|control11|><|separator|>
  58. [58]
    Horse Strangles | Brazos Valley Equine Hospitals
    75% of horses will develop immunity after a Strep equi infection, leaving 25% susceptible to reinfection within months of resolution. Use of antibiotics may ...
  59. [59]
    Equine strangles: diagnosis, treatment, and options for prevention ...
    Strangles is a result of bacterial infection with Streptococcus equi subspecies equi (referred to as S. equi). The disease has been in the equine population ...Missing: influx | Show results with:influx
  60. [60]
    Infectious Diseases and the International Movement of Horses - PMC
    It has been repeatedly shown that movement of equids and trade in semen represent the most important factor responsible for the spread of equine diseases. With ...
  61. [61]
    Evaluating Trends in Strangles Outbreaks Using Temperature and ...
    Strangles is a highly contagious equine disease of the upper respiratory tract that is caused by Streptococcus equi subspecies equi (SEE). This disease can be ...
  62. [62]
    Strangles: preventive strategies and linking research to action
    May 20, 2025 · Strangles is a bacterial equine disease reported in veterinary literature as early as the 13th and 17th centuries.
  63. [63]
    [PDF] National List of Reportable Animal Diseases - usda aphis
    Immediate reporting by Animal Health Professionals. Monitored Diseases ... • Strangles (Streptococcus equi equi). Farmed Cervid. • None at this time.Missing: mandatory | Show results with:mandatory
  64. [64]
    Strangles in Arabian horses in Egypt: Clinical, epidemiological ... - NIH
    These findings are in agreement with the results of Helal and Hassan [7,17], in Egypt who found the prevalence rates of strangles in horse was 19.57% and 20.6%, ...Missing: global | Show results with:global